MoonLake Immunotherapeutics
Close on Oct 19, 2026
- Market cap
- $720.67M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | – | $-0.84 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 23, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | – | $-1.10 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | Before market open | – | – | – |
Press releases
Announcements MoonLake Immunotherapeutics filed with the SEC
PRESS RELEASE, DATED AUGUST 10, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 21, 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SLIDE PRESENTATION, DATED JUNE 22, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 22, 2026
Material agreement · Results of operations · New financial obligation · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JANUARY 8, 2026
Other events · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 28, 2025
Other events · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 3, 2025
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 10, 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MARCH 10, 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SLIDE PRESENTATION, DATED MARCH 10, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 26, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
W: moonlaketx.com | E: [email protected]© 2023 | Proprietary | MoonLake TX MoonLake Immunotherapeutics R&D Day Webcast Presentation Document – Results ARGO trial November 6th 2023
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE, DATED OCTOBER 15, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
MOONLAKE IMMUNOTHERAPEUTICS CAPITAL MARKETS DAY PRESENTATION DATED SEPTEMBER 11, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 10, 2023
Results of operations · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody ® sonelokimab in hidradenitis suppurativa
Regulation FD disclosure · EX-99.1 to Form 8-K
W: moonlaketx.com | E: [email protected]© 2023 | Proprietary | MoonLake TX MoonLake Immunotherapeutics R&D Day Webcast Presentation Document – Results MIRA trial June 26th 2023
Regulation FD disclosure · EX-99.2 to Form 8-K
MOONLAKE IMMUNOTHERAPEUTICS CAPITAL MARKETS DAY PRESENTATION DATED APRIL 19, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
MOONLAKE IMMUNOTHERAPEUTICS. CAPITAL MARKETS DAY PRESENTATION DATED JUNE 7, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY MOONLAKE IMMUNOTHERAPEUTICS ON APRIL 5, 2022
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
MOONLAKE IMMUNOTHERAPEUTICS UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF DECEMBER 31, 2021 AND THE UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2021
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE, DATED OCTOBER4, 2021
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED OCTOBER 2021
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Thank you for joining our call today. In this call, we'll be discussing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K